ENTERO.NS
ENTERO.NS
INE010601016
ENTERO HEALTHCARE SOLU L
Loading chart...

Company Profile

Entero Healthcare Solutions Limited engages in the trading of pharmaceutical and surgical products in India. The company offers a range of pharmaceuticals and other healthcare products to retail pharmacies and healthcare practitioners; and healthcare products, including pharmaceutical and nutraceutical products and vaccines; medical devices, such as orthopaedic implants and coronary stents; and hospital consumables comprising examination and surgical gloves, syringes, needles, and sutures to hospitals and clinics. It also provides private label products under the Entero Surgicals private label, such as monitoring devices, nursing and rehabilitation products, and consumables; commercial solutions; and healthcare product distribution solutions, including imports, central warehousing, redistribution, last mile delivery, and connection with the pharmacies, hospitals, and clinics. The company was incorporated in 2018 and is based in Mumbai, India.

Related stocks

200028.SZ
200028.SZ • China
ACCORD-B
12 HKD
936.21M USD 1Y -3.3%
8129.T
8129.T • Japan
TOHO HOLDINGS CO LTD
3,687 JPY
1.51B USD 1Y -31.5%
603368.SS
603368.SS • China
GUANGXI LIUYAO GROUP CO LTD
15.48 CNY
920.07M USD 1Y -18%
9987.T
9987.T • Japan
SUZUKEN CO LTD
2,600 JPY
2.19B USD 1Y -12.6%
2784.T
2784.T • Japan
ALFRESA HOLDINGS CORP
2,230 JPY
2.47B USD 1Y +4.2%
000028.SZ
000028.SZ • China
SINOPHARM ACCORD
19.96 CNY
1.83B USD 1Y -13.1%
000950.SZ
000950.SZ • China
CQP
5.34 CNY
1.37B USD 1Y +3.5%
600056.SS
600056.SS • China
CHINA MEHECO GROUP CO LTD
9.14 CNY
2.05B USD 1Y -19.3%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
3Y Volatility
41.0% p.a.
Max Drawdown (3Y)
-38.7%
Sharpe Ratio (3Y)
0.32
Beta Factor
-0.49
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 58.2 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
ende